. Overview We are a leader in the field of gene therapy, seeking to deliver to patients suffering from rare and other devastating diseases single treatments with potentially curative results. We are advancing a focused pipeline of innovative gene therapies, including our clinical candidates for the treatment of Huntingtons disease, refractory mesial temporal lobe epilepsy (MTLE), Fabry disease, and amyotrophic lateral sclerosis caused by mutations in superoxide dismutase 1 (SOD1-ALS). Recent Pro...
Q2 FY2026 — expected 2026-09-26
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-02 | 2025-12-31 | 0001104659-26-021898 | EDGAR | 107K words |
| 2025-02-27 | 2024-12-31 | 0001558370-25-001699 | EDGAR | — |
| 2024-02-28 | 2023-12-31 | 0001558370-24-001915 | EDGAR | — |
| 2023-02-27 | 2022-12-31 | 0001558370-23-002110 | EDGAR | — |
| 2022-02-25 | 2021-12-31 | 0001558370-22-002050 | EDGAR | — |
| 2021-03-01 | 2020-12-31 | 0001558370-21-002186 | EDGAR | — |
| 2020-03-02 | 2019-12-31 | 0001558370-20-001883 | EDGAR | — |
| 2019-02-28 | 2018-12-31 | 0001558370-19-001305 | EDGAR | — |
| 2018-03-14 | 2017-12-31 | 0001558370-18-002042 | EDGAR | — |
| 2017-03-15 | 2016-12-31 | 0001047469-17-001589 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-10 | 2025-09-30 | 0001104659-25-108813 | EDGAR | 62K words |
| 2025-07-29 | 2025-06-30 | 0001558370-25-009694 | EDGAR | — |
| 2025-05-09 | 2025-03-31 | 0001558370-25-007068 | EDGAR | — |
| 2024-11-05 | 2024-09-30 | 0001558370-24-014346 | EDGAR | — |
| 2024-08-01 | 2024-06-30 | 0001558370-24-010528 | EDGAR | — |
| 2024-05-07 | 2024-03-31 | 0001558370-24-006914 | EDGAR | — |
| 2023-11-07 | 2023-09-30 | 0001558370-23-017867 | EDGAR | — |
| 2023-08-01 | 2023-06-30 | 0001558370-23-012633 | EDGAR | — |
| 2023-05-09 | 2023-03-31 | 0001558370-23-008658 | EDGAR | — |
| 2022-11-02 | 2022-09-30 | 0001558370-22-015906 | EDGAR | — |
| 2022-08-08 | 2022-06-30 | 0001558370-22-012523 | EDGAR | — |
| 2022-05-02 | 2022-03-31 | 0001558370-22-006570 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-02 | 0001104659-26-021890 | EDGAR | 4K words |
| 2026-01-13 | 0001104659-26-003075 | EDGAR | — |
| 2026-01-09 | 0001104659-26-002317 | EDGAR | — |
| 2025-12-04 | 0001104659-25-118292 | EDGAR | — |
| 2025-11-10 | 0001104659-25-108802 | EDGAR | — |
| 2025-11-03 | 0001104659-25-105223 | EDGAR | — |
| 2025-09-29 | 0001104659-25-094011 | EDGAR | — |
| 2025-09-24 | 0001104659-25-092750 | EDGAR | — |
| 2025-09-24 | 0001104659-25-092740 | EDGAR | — |
| 2025-07-29 | 0001104659-25-071441 | EDGAR | — |
268 total filings indexed. 236 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001590560 |
| Ticker | QURE |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Website | https://www.uniqure.com |
| Listed | 2014-02-05 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report